MYOCARDIAL VIABILITY TESTING AND THE EFFECT OF EARLY INTERVENTION IN PATIENTS WITH ADVANCED LEFT VENTRICULAR SYSTOLIC DYSFUNCTION, by Tarakji et al.
Controversy remains regarding the role of revascularization in patients with heart failure and left ventricular dysfunction. Observational studies suggest that such patients with preserved viability and ischemia benefit from revascularization, but definitive recommendations are constrained by limitations and biases inherent in cohort analyses. In this issue of Circulation, Tarakji and colleagues report on patients referred for positron-emission tomography imaging of viability during consideration of revascularization. Propensity scoring was used to match patients who underwent revascularization to a group that was treated medically. Revascularization was associated with a 48% reduction in the risk of mortality over 3 years. Of interest, the modeled outcomes suggested only minor influence of the extent of viability on the effect of revascularization. Short of a full randomized trial, these data provide the most robust analysis to date of the potential role of revascularization in patients with left ventricular dysfunction. In an accompanying editorial, Gibbons and colleagues (p 180) place these results in context of previous observational studies and ongoing randomized trials, and examine the strengths and weaknesses of such an analytic approach. See p 230.
RANDOMIZED TRIAL OF A NONPOLYMER-BASED RAPAMYCIN-ELUTING STENT VERSUS A POLYMER-BASED PACLITAXEL-ELUTING STENT FOR THE REDUCTION OF LATE LUMEN LOSS, by Mehilli et al.
Although drug-eluting stents (DES) reduce restenosis and the need for repeat revascularization procedures, concerns over the long-term safety of these devices persist. DES utilize polymers to deliver antirestenotic drugs. The possibility that polymers may promote inflammatory and thrombotic processes and adversely affect vessel wall healing has led to the development of polymer-free stents with a microporous surface as an alternative for local drug delivery. The ISAR-TEST (Intracoronary Stenting and Angiographic RestenosisTest Equivalence Between 2 Drug-Eluting Stents Trial) investigators studied whether polymer-free stents coated in the cardiac catheterization laboratory with 2% rapamycin solution are not inferior to polymer-based paclitaxel-eluting stents for the prevention of restenosis. They showed no significant differences in in-stent late lumen loss, angiographic restenosis, or target lesion revascularization rates between the nonpolymer rapamycin-stent and polymer paclitaxel-stent groups. Additional studies are necessary to determine the impact of this non-polymer stent system on long term safety end points. See p 273.
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Venous Thromboembolism in Children. See p e12. 
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